Here’s a quick look at the stocks that are likely to be in focus in today’s trading.

Trento And Bharat Electronics: In a significant move by the National Stock Exchange (NSE), Trent and Bharat Electronics Limited (BEL) will be included in the prestigious Nifty 50 index with effect from September 30. This restructuring underlines the growing importance of these companies in the Indian equity markets. Trent, known for its strong retail presence, and BEL, a leading company in the defense electronics space, will replace Divi’s Laboratories and LTIMindtree, which will exit the index.

Ambuja cement: GQG Partners has further increased its investment in Ambuja Cement, increasing its stake to 2.5 percent by acquiring an additional 1.1 percent through block deals worth ₹1,679 crore. The purchase price was ₹625.5 per share, reflecting GQG Partners’ continued confidence in the Company’s growth prospects.

Hero MotoCorp: Hero Motors, the leading auto components division of the Hero Group, has applied for an initial public offering (IPO) with the Securities and Exchange Board of India (SEBI). The company aims to raise up to ₹900 Crore through public issue, which marks a significant step in the expansion plans.

ONGC: Oil and Natural Gas Corporation (ONGC) has achieved a milestone with the commencement of production from its fifth oil well at KG-DWN-98/2 Cluster-2 site. In addition, ONGC has successfully commissioned a gas export pipeline connecting the offshore site with the onshore terminal, further enhancing its operational capabilities.

Transport Company of India: The board of Transport Corporation of India has approved a buyback of up to 13.33 lakh shares ₹1,200 per share, a premium of 4.5 percent over the previous Friday’s closing price. The buyback is scheduled to take place on September 4th as the record date and reflects the company’s commitment to returning value to its shareholders.

Alembic Pharma: Alembic Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for betamethasone valerate foam (0.12%). This product is a generic equivalent to Luxiq foam (0.12%) and is used to treat scalp conditions, providing a new treatment option to patients in the U.S. market.

KEC International: KEC International secured orders worth ₹1,079 crore in the transmission and distribution (T&D) and cable segments. The new contracts include projects from a private developer in India and orders for transmission lines in Saudi Arabia, Oman and the United Arab Emirates. This brings the company’s order intake since the beginning of the year to over ₹8,700 crore, which underlines the strong momentum of its business.

IDFC First Bank: IDFC First Bank has issued an income tax refund of ₹202.55 crore for the fiscal year 2023-24. The refund includes ₹189.25 crore in taxes and ₹13.30 crore in interest, which boosted the bank’s finances.

Ashoka Buildcon: Ashoka Buildcon is the lowest offer for a ₹478 crore project awarded by the Mumbai Metropolitan Region Development Authority (MMRDA). The project involves design and construction of an elevated road connecting key areas including Kalyan-Murbad Road and Pune Link Road and will include an approach road and a crossing over the Karjat-Kasara railway line. This award further strengthens Ashoka Buildcon’s position in infrastructure development.

Piramal Companies: Piramal Capital and Housing Finance, a subsidiary of Piramal Enterprises, has partnered with the Central Bank of India to expand their joint lending operations. This strategic alliance aims to improve financial inclusion by targeting middle and low-income borrowers in rural and semi-urban areas, thereby expanding credit access to underserved regions.

Jio Financial Services: Jio Financial Services has received approval from the Ministry of Economic Affairs to increase its foreign investment limits to 49 percent of its total equity on a fully diluted basis. The move is expected to attract significant foreign investment and improve the company’s financial flexibility and growth prospects.

FDC: FDC Limited announced that its manufacturing facility in Baddi has successfully passed a US FDA inspection with no issues and no 483 defects, signaling full compliance with stringent regulatory standards. This flawless inspection reflects FDC’s commitment to maintaining high quality manufacturing processes.

Dr. Reddy’s Laboratories: Dr. Reddy’s Laboratories reported that the USFDA conducted a pre-market inspection at its Srikakulam facility, which resulted in a Form 483 with three observations. The company has committed to resolving these observations within the stipulated timeline and ensuring compliance with regulatory requirements.